Articles tagged "Induction therapy"

2018 American Transplant Congress
Hepatitis C Recurrence after Liver Transplant: A Comparison of Antibody Induction versus No Antibody Induction
S. Patel, J. Jin, E. Benedetti, P. West-Thielke.
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplant (OLT) is universal and exhibits accelerated progression to cirrhosis. Progression can be mitigated by new…
2018 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
Q. Gao, R. Davis, M. Mulvihill, M. Song, F. Leopardi, M. Ribeiro, T. How, G. Devi, B. Collins, A. Kirk.
Department of Surgery, Duke University Medical Center, Durham, NC.
IntroductionThe field of porcine islet xenotransplantation has made significant progress in non-human primate studies in recent years. However, one major barrier preventing clinical translation of…
2018 American Transplant Congress
T Cell Exhaustion in Kidney Transplant Patients
M. Fribourg,¹ C. Fischman,² L. Anderson,² B. Burrell,³ P. Heeger,² P. Cravedi.²
¹Department of Neurology, Icahn School of Medicine, New York; ²Department of Medicine, Icahn School of Medicine, New York; ³Immune Tolerance Network, Bethesda.
Background: T cell exhaustion is a dysfunctional state that arises during chronic infection and cancer in response to persistence of high antigenic load. Whether chronic…
2018 American Transplant Congress
Risk of Bacteremia According to Transplant Induction Immunosuppression Regimen
E. Misch, S. Kelley, G. Leverson, B. Astor, D. Kaufman.
University of Wisconsin School of Medicine and Public Health, Madison.
Background: Transplant immune suppression is designed to suppress the adaptive immune response and ensure graft survival, but may have unintended effects on innate immunity. Few…
2018 American Transplant Congress
The BEST Trial: A Prospective Randomized Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression
E. Woodle,¹ D. Kaufman,² A. Shields,¹ J. Leone,³ A. Wiseman,⁴ A. Matas,⁵ P. West-Thielke,⁶ E. King,¹ R. Alloway.¹
¹U Cincinnati, Cincinnati; ²U Wisconsin, Madison; ³Tampa General, Tampa; ⁴U Colorado, Denver; ⁵U Minnesota, Minneapolis; ⁶UIC, Chicago.
Previous large multicenter belatacept (BELA)-based CNI- and steroid-free immunosuppressive trials have not enrolled to completion due to safety concerns. The BEST Trial (Belatacept-based Early Steroid…
2018 American Transplant Congress
B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression
Q. Gao,¹ A. Mehta,² A. Guasch,² A. Ghali,² A. Kirk,¹ H. Xu.¹
¹Department of Surgery, Duke University Medical Center, Durham, NC; ²Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.
Alemtuzumab induction combined with belatacept and rapamycin (ABR) maintenance immunotherapy effectively prevents costimulation blockade resistant rejection (CoBRR). We longitudinally investigated kinetics of repopulating B cell…
2018 American Transplant Congress
A Comparison of Alemtuzumab versus Antithymocyte Globulin Induction in High-Risk, Non-Sensitized Renal Transplant Recipients
S. Patel, A. Lichvar, E. Benedetti, P. West-Thielke.
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Lymphocyte depleting induction is routinely utilized in high immunologic risk renal transplant (RTx). African Americans (AA) have a relatively higher risk of rejection regardless…
2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Heart/Kidney Transplantation
I. Moinuddin, J. Yu, L. Kang, C. Bhati, D. Bandyopadhyay, A. King, D. Kumar, L. Kamal, D. Tang, I. Yakubu, G. Gupta.
Virginia Commonwealth University, Richmond.
Introduction: There is no published data on the risks and benefits of Induction immunosuppression in simultaneous heart/kidney transplant (SHKT) patients.Methods: We analyzed all SHKT performed…
2018 American Transplant Congress
Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction
Q. Gao,¹ A. Mehta,² A. Guasch,² L. Stempora,¹ A. Kirk,¹ H. Xu.¹
¹Department of Surgery, Duke University Medical Center, Durham, NC; ²Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.
Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…
2018 American Transplant Congress
The Influence of Rabbit Antithymocyte Globulin (rATG) Dose on the Incidence of CMV Infection in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis. A Propensity Score Matched Cohort Analysis
M. Ivani de Paula,^1,2 S. Bae,¹ J. Garonzik-Wang,¹ C. Felipe,² M. Cristelli,² A. Massie,^1,3 J. Medina-Pestana,² D. Segev,^1,3 H. Tedesco Silva J�nior.²
¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Nephrology, Hospital do Rim, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; ³Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, Brazil.
rATG has become the agent of choice for induction therapy in sensitized patients and those receiving expanded criteria donors (ECD) allografts. However, the optimal dose…